A Study of Tasisulam in Treating Participants With Malignant Melanoma

Participants will receive a 2-hour intravenous infusion of study drug (tasisulam) once every
28 days. Radiological imaging scans will be performed before the first dose of study drug and
then after every other treatment. Participants will be assessed for clinical progression at
every visit and for response approximately every 56 days (every other cycle).

Inclusion Criteria:

- Diagnosis of malignant melanoma that is unresectable or metastatic (Stage III or IV)

- Have received 1 previous systemic treatment regimen for unresectable or metastatic
melanoma. An immunotherapy or antibody-based regimen (including vaccination-based
treatments) is not counted as a prior treatment regimen for determining study
eligibility, unless it was combined with a chemotherapeutic or targeted anti-cancer
drug.

- Have discontinued all previous therapies for cancer, including chemotherapy,
radiotherapy, immunotherapy, or other investigational therapy for at least 30 days

Exclusion Criteria:

- Serious pre-existing medical conditions

- Have received two or more previous treatment regimens for unresectable or metastatic
melanoma

- Have a second primary cancer (unless disease-free to more than 2 years)

- Active treatment with Warfarin (Coumadin)

- Primary ocular or mucosal melanoma